BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1 tyrosine kinase inhibitors (TKIs). The third-generation ABL1 TKI ponatinib is effective against BCR-ABL1 point mutants individually, but remains vulnerable to certain BCR-ABL1 compound mutants. To determine the f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Khorashad, Jamshid S., Kelley, Todd W., Szankasi, Philippe, Mason, Clinton C., Soverini, Simona, Adrian, Lauren T., Eide, Christopher A., Zabriskie, Matthew S., Lange, Thoralf, Estrada, Johanna C., Pomicter, Anthony D., Eiring, Anna M., Kraft, Ira L., Anderson, David J., Gu, Zhimin, Alikian, Mary, Reid, Alistair G., Foroni, Letizia, Marin, David, Druker, Brian J., O'Hare, Thomas, Deininger, Michael W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548169/
https://ncbi.nlm.nih.gov/pubmed/23223358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-431379
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados